Abstract: The present disclosure is directed to the use of a composition comprised of: (1) a first active blend of at least: (a) Jojoba oil/Macadamia seed oil esters; (b) squalene; (c) phytosteryl macadamiate; and (d) phytosterols; (2) a second active blend of at least: (e) EGF growth factor; (f) IGF-1 growth factor; (g) acidic FGF growth factor; (h) basic FGF growth factor; (i) VEGF growth factor; (j) vitamin B9; and (k) acetyl glutamine; and (3) a third active blend of at least: (l) an extract of lithothamnium calcareum; (m) pentylene glycol; (n) lactic acid; and (o) glycerin; (4) an emulsifier; and (5) a dermatologically acceptable carrier which, when applied onto skin, helps to positively influence inflammation, hydration, and keratinocyte hyperproliferation, thereby supporting skin barrier health, integrity, and functionality.

Abstract: The present invention provides a novel radiosensitizer or anti-cancer chemotherapy sensitizer. In particular, the invention provides a radiosensitizer or anti-cancer chemotherapy sensitizer that can relieve the irritation of an affected area caused by hydrogen peroxide, is safe when injected into a human body, and can delay or reduce the degradation of hydrogen peroxide and thereby can efficiently exert a radiation sensitizing effect and an anti-cancer chemotherapy sensitizing effect. The radiosensitizer or anti-cancer chemotherapy sensitizer comprises a combination of (a) hydrogen peroxide and (b) hyaluronic acid or salt thereof.

Abstract: The present disclosure relates to injectable compositions sterile injectable fluid compositions comprising a polysaccharide having a color in the visible spectrum, methods of forming the same, kits containing the same, and methods for performing agent-assisted procedures in a patient using the same.

Abstract: The present invention relates to a microneedle system (MNS) for intradermal application in a controlled release of glucagon-like peptide analogues.

Abstract: A polymer ring configured to fit around or adjacent to an intraocular lens is described. The polymer ring comprises a hyaluronic acid derivative and a drug. An intraocular lens comprising a polymer ring positioned on or adjacent to the intraocular lens is also described. In addition, a method of delivering a drug to an eye of a subject is described. The method includes inserting an intraocular lens into the eye of the subject, and positioning polymer ring onto at least a portion of the intraocular lens, wherein the polymer ring comprises a hyaluronic acid derivative and a drug.

Abstract: The present disclosure relates to a formulation comprising tocotrienols and derivatives thereof, for transmucosal (such as buccal, sublingual and mucosal) administration.

Abstract: This disclosure relates to oral film dosage formulations and processes for preparing oral film dosage forms for the delivery of poorly water-soluble drugs and more particularly to the preparation of oral film dosage forms that are suitable for cannabis drug delivery.

Abstract: Compactable gastric residence systems comprising therapeutic agent formulations for sustained gastric release of therapeutic agents are disclosed, as well as methods and systems for encapsulating such gastric residence systems. The methods and systems for encapsulating the gastric residence systems can be automated from receiving a bulk of gastric residence systems, orienting, placing, compacting, securing, and encapsulating the gastric residence systems.

Abstract: The invention provides a dosage form and a bolus configured for administration to an animal, wherein said dosage form and said bolus is configured to release a methane inhibitor to the animal over a period of time. Preferably the methane inhibitor is a haloform. Also provided is the use of the bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

Abstract: Disclosed herein are thermosensitive hydrogels including at least one thermosensitive polymer and at least one polypeptide. The hydrogels may further include one or more therapeutic and/diagnostic agents and can be used to selectively and controllably deliver such agents to specified tissues and organ systems.

Abstract: Pharmaceutical composition comprising growth-hormone releasing peptide 6 (GHRP-6), tartrate buffer at pH 5.0-6.0, and trehalose as stabilizing agent, as well as the use of said composition for the manufacture of a medicament. The invention also provides a kit of parts comprising said pharmaceutical composition and a method of treatment of an individual in need thereof, which entails the administration of a therapeutically effective amount of the pharmaceutical composition comprising of GHRP-6, tartrate buffer at pH 5.0-6.0 and trehalose.

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Abstract: The present disclosure generally relates to systems and methods for treating or preventing aging skin or other indications. For example, some aspects are generally directed to systems and methods for administering a conjugate of a dendrimer and A-acetyl-L-cysteine to a subject, e.g., to the skin of a subject. For example, in one set of embodiments, the conjugate may be applied to aging skin, e.g., to treat or reverse the appearance of aging in the skin. Surprisingly, even though such conjugates can be relatively large (e.g., greater than 3 or 4 nm in diameter) and normally difficult to administer, formulations such as those described herein are effective at facilitating transdermal drug delivery of the conjugates. In addition, in addition to aging skin, other indications may be treated in certain aspects, for example, if the subject has or is at risk of a brain injury or a neurological disorder.

Abstract: The present invention provides oral pharmaceutical composition comprising Arsenic trioxide and one or more pharmaceutically acceptable excipients for use in the treatment of acute promyelocytic leukemia and other cancers like acute myeloid leukemia. Further, the present invention provides a process for the preparation of the said composition.

Abstract: The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended release tablet. Compared with standard immediate-release dosage forms these tablets can permit a lower peak plasma concentration, Cmax, while maintaining plasma concentrations at therapeutic levels for a desired period. This can be used, for instance, to administer lower doses while still providing the same pharmacological effect.

Abstract: A sleep-regulating tablet allowing release by stages and a preparation method thereof are provided. The tablet structurally consists of a drug-containing delayed-release tablet core, a drug-free stomach-soluble coating, a drug-free enteric coating, a drug-containing immediate-release shell, and a shell stomach-soluble coating sequentially from inside to outside. An ideal dual-stage timed drug release mode may be realized, and is especially suitable for a sleep-regulating drug, such as ramelteon.

Abstract: A one-pot procedure to extract a dispersible exine shell. The shell can be used as a protection and/or delivery and/or removal vehicle for active substances or as an antioxidant. The invention provides a formulation containing the dispersible exine shell together with an active substance; and a method for preparing the shell by isolating a dispersible exine shell from a naturally occurring spore or pollen grain by treating the spore or pollen grain with a base or surfactant or both with or without a catalyst in the same reaction vessel.

Abstract: In an embodiment, the invention provides an isolated population of exosomes comprising interleukin-27 (IL-27) or interleukin-35 (IL-35). In an embodiment, the invention also provides a method of preparing a population of exosomes comprising interleukin-27 (IL-27), the method comprising: (a) isolating CD19+B2 cells or B1a cells; (b) activating the isolated cells with a LPS or a BCR agonist to provide activated cells; and (c) isolating exosomes secreted from the activated cells. In an embodiment, the invention also provides a method of preparing a population of exosomes comprising interleukin-35 (IL-35), the method comprising: (a) isolating CD138+plasma cells; (b) activating the isolated cells with a LPS or a BCR agonist to provide activated cells; and (c) isolating exosomes secreted from the activated cells. Additional embodiments of the invention are as described.

Abstract: The present disclosure provides a lipid nanoparticle and uses of the lipid nanoparticle for treating cancer, targeting integrin ?v?3, anti-angiogenesis to prevent cancer metastasis and reducing the cytotoxicity of anti-cancer drugs to normal cells. In addition, since it can inhibit angiogenesis, it also can be used in vascular related diseases. The lipid nanoparticle provides targeting cell surface integrin ?v?3, the nano-liposome specific against digestion system-related cancers locally and systemically. The lipid nanoparticle of the present disclosure would target cancer cells instead of normal cells. Even normal cells contain integrin ?v?3, however, the lipid nanoparticle of the present disclosure only recognizes the conformation of integrin ?v?3 on the cancer cells. The lipid nanoparticle of the present disclosure can equip with other targeting molecules, payload with other anti-cancer drugs, and can combine with radiation therapy and reduce radiation therapeutic threshold.

Abstract: The present invention relates to a method of preparing a nanoparticle comprising at least one cell-penetrating peptide (CPP) and a cargo molecule, said method comprising the steps: preparing a CPP solution comprising a CPP, a dry alcohol; and 1-50% (v/v) of an aprotic solvent; diluting the CPP solution in water to a concentration of 2 to 500 ?M, and adding the cargo molecule to the CPP solution to obtain a CPP:CM mixture; whereby nanoparticles comprising CPP and cargo molecule are formed. The invention further relates to a nanoparticle obtained or obtainable by the method, as well as pharmaceutical compositions comprising such nanoparticles.

Abstract: A nanoparticle preparation system, a control method of the nanoparticle preparation system, an electronic device, a non-transitory computer readable medium, and a method for preparing nanoparticles using the nanoparticle preparation system are disclosed. The nanoparticle preparation system includes a mixing element, a first liquid suction device and a second liquid suction device. The mixing element includes a plurality of mixing channels; the first liquid suction device includes a plurality of first liquid suction tubes arranged in rows along a first direction and configured to input a first preparation solution into the plurality of mixing channels through first inlets of the mixing channels, respectively; and the second liquid suction device includes a plurality of second liquid suction tubes arranged in rows along a second direction and configured to input a second preparation solution into the plurality of mixing channels through second inlets of the mixing channels, respectively.

Abstract: The present invention relates to electrospun fibres containing: i) a first and a second hydrophilic fibre-forming polymer that is soluble in a hydrophilic solvent, ii) a bioadhesive substance that is slightly soluble in said hydrophilic solvent, iv) a drug substance, wherein the first hydrophilic polymer has a solubility in water at 37° C. that is at least 10 times greater than the solubility in water at 37° C. of the second hydrophilic fibre-forming polymer, and wherein the bioadhesive substance is present in solid form.

Abstract: Devices and methods for selectively accessing tissue for sensing or drug release are provided. A device includes an array of wells formed in a substrate supporting a plurality of membranes. Each membrane is disposed at a well opening of one of the wells of the array. The device further includes an actuator and electronics configured to control the actuator to supply a vibration through the substrate. The supplied vibration is configured to selectively rupture one of the plurality of membranes at a defined timepoint to selectively give access to tissue through a well opening.

Abstract: A diclofenac-containing patch package product, in which a diclofenac-containing patch, including an adhesive layer containing diclofenac sodium as a drug and dimethyl sulfoxide as a solvent, and a backing layer, is sealed in a packaging bag, the packaging bag being formed of a laminate at least comprising: an innermost layer composed of at least one selected from the group consisting of polyethylene terephthalate and cycloolefin polymer; an oxygen barrier layer arranged outside the innermost layer; and an outer layer arranged outside the oxygen barrier layer.

Abstract: Provided herein are compositions, systems, and methods for causing weight loss and treating and/or preventing a disease or condition, such as obesity, diabetes, and cancer, with an agent or procedure that inhibits the TMA/FMO3/TMAO pathway in a subject.

Abstract: Provided herein are compositions, systems, kits, and methods for treating a subject with a disease or condition by administering a composition comprising fullerenes to the subject such that H2S is generated in said subject. In certain embodiments, the disease or condition is associated with inflammation and/or below normal H2S levels. In certain embodiments, the fullerenes are polyhydroxy fullerenes (PHFs).

Abstract: The present invention relates to a composition for preventing, alleviating or treating sarcopenia, containing D-ribo-2-hexulose as an active ingredient. D-ribo-2-hexulose of the present invention is a sweetener capable of replacing sugar, is harmless to the human body and does not cause side effects in normal cells so as to be safe for the human body, inhibits the degradation of myoproteins, and can exhibit muscle strengthening effects by increasing muscle mass, and thus the present invention is expected to be effectively usable in the prevention, alleviation or treatment of sarcopenia.

Abstract: Brain function may be improved by administering a therapeutically effective amount of 1,3-butanediol, selected from R-1,3-butanediol, S-1,3-butanediol, and racemic 1,3-butanediol, in combination with a therapeutically effective amount of cannabidiol (CBD). The disclosed compositions include synergistically effective amounts of 1,3-butanediol in combination with a synergistically effective amount of cannabidiol (CBD). The compositions may be administered to a subject for treating anxiety, concussion, traumatic brain injury (TBI), and/or cognitive impairment.

Abstract: The present disclosure provides a feed additive composition and a feed for livestock; a method of breeding livestock or improving the weight gain of livestock, comprising letting livestock to take said feed for livestock; and a use of the feed for livestock for improving the weight gain of livestock.

Abstract: Proposed is 2E-1-2-aminophenyl-3-3-nitrophenyl-2-propen-1-one (BIA) or its analogues relate to the use of the prevention, treatment and improvement of diseases characterized by the development of abnormal cells or cancer. The BIA and its analogues presented in this disclosure inhibit the calcium-free function of the BI-1 (TMBIM6) gene, thereby reducing binding to mTORC2, and reduce mTORC1 and mTORC2 activity and recruiting ribosomes. It reduces and ultimately inhibits AKT, which has the effect of inhibiting cancer growth.

Abstract: A method may formulate a composition to contain a predetermined dosage amount of choline and succinate in a molar ratio of choline to succinate of 2:1 that is effective to reduce a frequency and/or a severity of one or more symptoms selected from skeletal muscle weakness, skeletal muscle pain, low skeletal muscle tone, physical exercise intolerance, lack of muscular endurance, and loss of skeletal muscle mass in a human subject consuming the composition during an initial course of treatment. A method may provide to the human subject, the composition containing the predetermined dosage amount of choline and succinate in the molar ratio of choline to succinate of 2:1. In some examples, the composition may be formulated to increase skeletal muscle mass. In some examples composition may further include a nicotinamide component and/or a creatine component.

Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula I or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

Abstract: The present disclosure provides a therapy for diabetes that targets abnormal stem cells by HDAC inhibitors in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells by HDAC inhibitors in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells by HDAC inhibitors in combination with stem cell migration, in a subject in which abnormal stem cells have been detected.

Abstract: A chewable composition is provided. The composition includes a gelling component in a sufficient amount to provide a cohesive gelled product and not more than 1.5% w/w and an active pharmaceutical ingredient (API), wherein the chewable composition has a gel strength up to 10,000 g, measured by pressing force test.

Abstract: The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.

Abstract: Disclosed are methods of using a naproxen fill formulation suitable for encapsulation into a soft gel dosage unit to treat inflammation and pain. Methods include administering naproxen to a subject in need thereof to treat pain and inflammation. Methods can include administering naproxen together with another medicament to a subject in need thereof to treat an additional condition such as a cough, cold, allergy, congestion, etc.

Abstract: Topical naproxen formulations comprising long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide (“DMSO”), wherein the formulation comprises about 5.0 wt % or less water and is preferably anhydrous.

Abstract: An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.

Abstract: Disclosed herein is a method of treating opioid use disorder in a subject comprising administering an effective amount of pregabalin or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure is directed to novel ophthalmic formulations comprising a gabapentinoid and methods for treating corneal pain using said formulations.

Abstract: The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same.

Abstract: Disclosed herein relates to compositions of and methods for the treatment of skin damage and/or wounds, while simultaneously relieving pain and/or cosmetic damage. As such, the present disclosure relates to an anhydrous topical composition for retarding and/or inhibiting scarring of a wound, burn and/or skin condition located on the skin of a subject while retaining a natural characteristic and/or elasticity of the skin. The anhydrous topical composition may comprise MCT, monolaurin, cetyl esters, marine oil, vegetable oil having an omega 3 fatty acid content greater than 9 wt %, and/or hempseed oil. Additionally, the anhydrous topical composition may comprise antimicrobial properties and/or characteristics, such that the anhydrous topical composition may be configured to inhibit any pathogen (e.g., a bacteria, a virus, a fungus, etc.) within the wound, burn and/or skin condition, when applied to the skin of the subject.

Abstract: Provided is a composition for preventing or treating cerebrovascular disease in a subject, comprising an activator of peptidylarginine deiminase 4.

Abstract: A method of attenuating opioid induced ventilatory and/or respiratory depression and/or augmenting opioid induced analgesia in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or an adduct, a pharmaceutically acceptable salt, a tautomer, or a solvate thereof.

Abstract: The present invention is directed to nanosuspensions of salsalate and methods of making and using such compositions.

Abstract: Provided is a method for preventing or treating a liver disease, including administering a therapeutically effective amount of pharmaceutical composition to a subject in need, and the pharmaceutical composition includes the isothiocyanate structural modified compound and a pharmaceutically acceptable carrier thereof.

Abstract: A copper chelating agent that contains at least one compound selected from the group consisting of a compound represented by Formula (1), a compound represented by Formula (2), a compound represented by Formula (3), a compound represented by Formula (4), a salt thereof, and a solvate thereof:

Abstract: The present invention discloses a sustained release non-aqueous injectable composition of buprenorphine, its metabolite, its prodrug, or its salt thereof for the treatment of moderate-to-severe pain and opioid dependence. The non-aqueous injectable composition includes one or more biocompatible non-aqueous solvents, one or more release retarding agents, one or more surfactants, one or more biodegradable polymers and one or more stabilizers. The buprenorphine composition of the present invention delivers buprenorphine over a period of about one week to 12 weeks after single administration which leads to better patient compliance by reducing the daily dose administration of buprenorphine. The present invention also provides an injectable composition with potentially less pain due to the use of smaller gauge needles wherein the suitable gauge of needle may be 23 gauge to 30 gauge with a length of 8 to 30 mm. The preferred size of needle is 25 to 30 gauge.

Abstract: The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

Abstract: The present disclosure provides a method for improving bioavailability of an NAD+ derivative. The method improves the bioavailability of the NAD+derivative by arranging a CD38 inhibitor and the NAD+ derivative in a same preparation, and controlling the CD38 inhibitor to release first rapidly, and then the NAD+ derivative releases after the CD38 inhibitor has taken effect, thereby increasing the level of NAD+ in vivo.